ClinicalTrials.gg
WithdrawnNCT05952518Updated Oct 22, 2026

PNS vs RFA for Facet Joint Pain

An interventional study of Sprint PNS system and Radiofrequency Ablation in Facet Joint Pain, sponsored by Penn State University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Penn State University · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Difficulty recruiting patients. Study is in close out process.
Updated Oct 22, 2026Now WithdrawnStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Arthralgia with a site in United States — 17 open to participants now, 23 under way, 4 of them phase 3. Arthralgia · United States.

Enrollment
85th of 88
0 · median 82
Started
2026
with 7 others
No phase
46 of 106
8 open now
Registered
92nd of 106
by date

Among the 106 studies in Arthralgia with a site in United States, this one is the 85th largest by enrollment of the 88 interventional ones that give a count, is one of 8 that started in 2026, is one of 46 with no phase, and was the 92nd registered.

Arthralgia

277 studies on the registry are indexed under Arthralgia; 54 are open to participants now.

Browse Arthralgia studies →

Open to participants now

17 of the 106 studies in Arthralgia with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Arthralgia studies recruiting now, 18 (51%) set no upper age limit and 16 (46%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Arthralgia with a site in United States, or all of them as a file.
02

Study summary

Radiofrequency ablation of the medial nerve is the current surgical treatment for back pain originating from the facet joints in the spine. However, this procedure causes denervation of spinal muscles. Peripheral nerve stimulation is another treatment for facet joint pain that may not cause damage to the spinal muscles. This study will compare both treatments in terms pain relief and spine biomechanics.

03

Conditions studied

  • Facet Joint Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range (18-80 years): The age range of the patient population at Hershey Medical Center with facet pain is 24 to 90 years old, with a mean age of 63 years old. Due to the physical tests planned in the study, the maximum age limit will be restricted to 80 years old.
  2. English Speaking: Adults who only speak other languages will not be included because of the lack of feasibility of employing reliable instruments and interviewers fluent in other languages.
  3. Facet Joint Pain: male and female patients having a diagnosis of facet joint pain based upon accepted diagnostic criteria (i.e., two positive nerve blocks) and assessed by an experienced physical therapist or physician.
  4. Indication for Surgical Procedure: Physical therapy is the of action for facet joint pain. If PT is not effective, patients are eligible for RFA or PNS.

Exclusion criteria

Exclusion Criteria:

  1. Previous Spinal Conditions Surgery: We will exclude patients with other spinal conditions like scoliosis or who have received previous spinal surgeries.
  2. Systemic neurological or neuromuscular disease: Such disorders (e.g., stroke, muscular dystrophy, myopathies) affect muscle and may confound muscle data and/or balance and physical performance data.
  3. Allergic reaction to ultrasound gels: It is possible, although rare, that patients develop allergic reaction to ultrasound gels. Those subjects will be excluded from the study.
  4. Physical Activity: Subjects will be asked to fill out the Physical Activity Readiness Questionnaire (PAR-Q), and if they answer yes to any of the questions, they need to be cleared by their physician prior to participating in the study.
  5. Current infection, illness, or condition: Individuals with a current infection, illness, or condition (e.g., uncontrolled blood pressure, pregnancy) that may affect their ability to safely participate will be excluded.
  6. Mental incompetency: Individuals who cannot legally consent themselves to the surgical procedure and participation in the research study, will not be considered for inclusion.
  7. Patients who have a Deep Brain Stimulation (DBS) system.
  8. Patients who have an implanted active cardiac implant (e.g. pacemaker or defibrillator).
  9. Patients who have any other implantable neuro-stimulator whose stimulus current pathway may overlap with that of the SPRINT System.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Peripheral Nerve Stimulation

    Peripheral nerve stimulation (PNS) is a procedure used to relieve chronic back pain by targeting the nerves responsible for transmitting pain signals from the back to the brain. It is a minimally invasive approach that aims to disrupt the pain signals and provide pain relief.

    Device: Sprint PNS system

  • Active comparator
    Radiofrequency Ablation

    Radiofrequency ablation (RFA) is the current standard of care for facet joint pain. It is a minimally invasive procedure used to relieve chronic back or neck pain caused by issues with the small joints in the spine called facet joints.

    Procedure: Radiofrequency Ablation

Interventions

  • DeviceSprint PNS system

    Temporary electrical stimulation of the medial nerve with implanted wires and wearable stimulator

  • ProcedureRadiofrequency Ablation

    Thermal ablation of the medial nerve

06

What researchers measure

Primary outcomes

  1. Multifidus muscle activity

    Muscle contraction quantification via shear wave elastography

    Time frame: pre-treatment

  2. Multifidus muscle activity

    Muscle contraction quantification via shear wave elastography

    Time frame: within two weeks of treatment completion

  3. Multifidus muscle activity

    Muscle contraction quantification via shear wave elastography

    Time frame: 12 months after pre-treatment measurement

Secondary outcomes

  1. Pain Intensity

    Visual Analog Scale, scale range 1 - 10, 10 being worse possible pain.

    Time frame: pre-treatment

  2. Pain Intensity

    Visual Analog Scale, scale range 1 - 10, 10 being worse possible pain.

    Time frame: within two weeks of treatment completion

  3. Pain Intensity

    Visual Analog Scale, scale range 1 - 10, 10 being worse possible pain.

    Time frame: 12 months after pre-treatment measurement

  4. Oswestry Disability Index

    Survey evaluating disability level, 0 - 4 No disability 5 - 14 Mild disability 15 - 24 Moderate disability 25 - 34 Severe disability 35 - 50 Completely disabled

    Time frame: pre-treatment

  5. Oswestry Disability Index

    Survey evaluating disability level, 0 - 4 No disability 5 - 14 Mild disability 15 - 24 Moderate disability 25 - 34 Severe disability 35 - 50 Completely disabled

    Time frame: within two weeks of treatment completion

  6. Oswestry Disability Index

    Survey evaluating disability level, 0 - 4 No disability 5 - 14 Mild disability 15 - 24 Moderate disability 25 - 34 Severe disability 35 - 50 Completely disabled

    Time frame: 12 months after pre-treatment measurement

  7. PROMIS-29 v2.0

    Survey assessing pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance)

    Time frame: pre-treatment

  8. PROMIS-29 v2.0

    Survey assessing pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance)

    Time frame: within two weeks of treatment completion

  9. PROMIS-29 v2.0

    Survey assessing pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance)

    Time frame: 12 months after pre-treatment measurement

  10. isometric back strength

    Measurement of peak force generated by the torso in extension in Newtons

    Time frame: pre-treatment

  11. Isometric back strength

    Measurement of peak force generated by the torso in extension in Newtons

    Time frame: within two weeks of treatment completion

  12. isometric back strength

    Measurement of peak force generated by the torso in extension in Newtons

    Time frame: 12 months after pre-treatment measurement

  13. Functional Reach

    distance between the length of an outstretched arm in a maximal forward reach, 10"/25 cm or greater Low risk of falls, 6"/15cm to 10"/25cm Risk of falling is 2x greater than normal, 6"/15cm or less Risk of falling is 4x greater than normal, Unwilling to reach Risk of falling is 8x greater than normal.

    Time frame: pre-treatment

  14. Functional Reach

    distance between the length of an outstretched arm in a maximal forward reach, 10"/25 cm or greater Low risk of falls, 6"/15cm to 10"/25cm Risk of falling is 2x greater than normal, 6"/15cm or less Risk of falling is 4x greater than normal, Unwilling to reach Risk of falling is 8x greater than normal.

    Time frame: within two weeks of treatment completion

  15. Functional Reach

    distance between the length of an outstretched arm in a maximal forward reach, 10"/25 cm or greater Low risk of falls, 6"/15cm to 10"/25cm Risk of falling is 2x greater than normal, 6"/15cm or less Risk of falling is 4x greater than normal, Unwilling to reach Risk of falling is 8x greater than normal.

    Time frame: 12 months after pre-treatment measurement

  16. Repetitive Trunk Rotation

    Time to complete 20 rotations, seconds, longer times are worse performance.

    Time frame: pre-treatment

  17. Repetitive Trunk Rotation

    Time to complete 20 rotations, seconds, longer times are worse performance.

    Time frame: within two weeks of treatment completion

  18. Repetitive Trunk Rotation

    Time to complete 20 rotations, seconds, longer times are worse performance.

    Time frame: 12 months after pre-treatment measurement

  19. Repeated Chair Stands

    Time to perform 5 repeated chair stands, higher times mean worse outcomes.

    Time frame: pre-treatment

  20. Repeated Chair Stands

    Time to perform 5 repeated chair stands, higher times mean worse outcomes.

    Time frame: within two weeks of treatment completion

  21. Repeated Chair Stands

    Time to perform 5 repeated chair stands, higher times mean worse outcomes.

    Time frame: 12 months after pre-treatment measurement

  22. Pfirmmann grade

    Degeneration of lumbar discs at the treated level, grade 1 - 5, 1 is normal and 5 is completely collapsed disc.

    Time frame: pre-treatment

  23. Pfirmmann grade

    Degeneration of lumbar discs at the treated level, grade 1 - 5, 1 is normal and 5 is completely collapsed disc.

    Time frame: within two weeks of treatment completion

  24. Pfirmmann grade

    Degeneration of lumbar discs at the treated level, grade 1 - 5, 1 is normal and 5 is completely collapsed disc.

    Time frame: 12 months after pre-treatment measurement

  25. t2-relaxation time

    T2 relaxation time of the disc at the treated level. Lower values indicate more degeneration.

    Time frame: pre-treatment

  26. t2-relaxation time

    T2 relaxation time of the disc at the treated level. Lower values indicate more degeneration.

    Time frame: within two weeks of treatment completion

  27. t2-relaxation time

    T2 relaxation time of the disc at the treated level. Lower values indicate more degeneration.

    Time frame: 12 months after pre-treatment measurement

  28. 2-point dixon MRI

    Intramuscular fat percentage, higher percentage means worse outcome.

    Time frame: pre-treatment

  29. 2-point dixon MRI

    Intramuscular fat percentage, higher percentage means worse outcome.

    Time frame: within two weeks of treatment completion

  30. 2-point dixon MRI

    Intramuscular fat percentage, higher percentage means worse outcome.

    Time frame: 12 months after pre-treatment measurement

07

Study locations

1 site
  • Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2026 to primary completion in Apr 2026, 0 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Feb 2026 → Apr 2026, primary completion Oct 2026 → Apr 2026 and completion Oct 2027 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2023
First posted
Jul 19, 2023
StartActual
Apr 8, 2026was Feb 2026
Primary completionActual
Apr 8, 2026was Oct 2026
CompletionActual
Apr 21, 2026was Oct 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Withdrawn Difficulty recruiting patients. Study is in close out process.
changed Oct 22, 2026
Start date
Feb 20, 2026→Apr 8, 2026 (actual)
Oct 22, 2026
Primary completion
Oct 2026→Apr 8, 2026 (actual)
Oct 22, 2026
Study completion
Oct 2027→Apr 21, 2026 (actual)
Oct 22, 2026
Enrollment
70 (estimated)→0 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Suspended→Withdrawn
    Why stopped Difficulty recruiting patients. Study is in close out process.
    Start date Feb 20, 2026→Apr 8, 2026 (now actual)
    Primary completion Oct 2026→Apr 8, 2026 (now actual)
    Study completion Oct 2027→Apr 21, 2026 (now actual)
    Enrollment 70 (estimated)→0 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05952518
Responsible party
Daniel Cortes (Associate Professor, Penn State University) — Principal investigator
First posted
Jul 19, 2023
Start date
Apr 8, 2026
Primary completion
Apr 8, 2026
Completion
Apr 21, 2026
Last update
Oct 22, 2026

Study contacts

Daniel H. Cortes, Ph.D.
principal investigator · Penn State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion